

## DIASTAT® AcuDial<sup>TM</sup> (diazepam rectal gel) Treatment: Order and Emergency Seizure Plan (To be completed by the physician)

Student name		
Treatment order	date	
AgeWeight		
Treatment:		
	liazepam rectal gel)	ma rootally pro for
	minutes OR for	
	hours	
	al nerve stimulator)	
, U	·	
011101		
• Call 911 if		
	stop by itself or with VNS within	minutes
	stop within minutes of giving	
		after seizure is over (no DIASTAT given)
		after seizure is over (after DIASTAT given)
Fallowing		
Following a	Child should rest in nurse's	Child may return to class
seizure:	office	5
	-	□ Parents/caregiver should
	Parents/caregiver should be	receive a not/copy of the seizure
	notified immediately	record sent home with the child
		record sent nome with the child
Dhysisian /Nursa	Practitioner/Physician's Assistant	Nama (Brintad)
•	•	Name (Finited)
Signature		Date
License #		State
Address		
Phone		

Developed in collaboration with Christine O'Dell, RN, MSN, and Shlomo Shinnar, MD, PhD, of the Comprehensive Epilepsy Management Center, Montefiore Medical Center, Bronx, New York.

## **CONFIDENTIALITY STATEMENT**

By creating and distributing the DIASTAT® (diazepam rectal gel) Back-to-School Booklet, it is the expressed intention of Valeant Pharmaceuticals North America to provide a value-added service to healthcare providers, caregivers, and patients. Valeant Pharmaceuticals North America intends to fully comply with HIPAA guidelines for patient confidentiality to ensure that personal information is not disclosed to anyone outside of those that the parent/caregiver, healthcare professional, or student-patient deem acceptable. Valeant Pharmaceuticals North America is not responsible for the DIASTAT Back-to-School Booklet or its contents after the booklet has been released to healthcare professionals. Careful consideration should be given before any medical information is released to others. **Important DIASTAT Information** 

DIASTAT is a gel formulation of diazepam intended for rectal administration in the management of selected, refractory, patients with epilepsy, on stable regimens of AEDs, who require intermittent use of diazepam to control bouts of increased seizure activity.

In clinical trials, the most frequent adverse event reported was somnolence (23%). Less frequent adverse events reported were dizziness, headache, pain, vasodilatation, diarrhea, ataxia, euphoria, incoordination, asthma, rash, abdominal pain, nervousness and rhinitis (1%-5%).

Please see enclosed full prescribing information.

© 2005 Valeant Pharmaceuticals North America